MarketPulse

women's health

5 articles
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

Organon Shares Soar 16.87% on Sun Pharma's $14/Share Acquisition

Sun Pharma agrees to acquire Organon for $14/share in all-cash deal, sending shares up 16.87% as women's health firm finds exit after struggling 2021 Merck spinoff.
BMYCELGrMRKPFEOGNacquisitionmerger
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Progyny Marks Decade in Women's Health With New Fertility Plan Launch

Progyny announces Q1 2026 earnings date and launches industry's first fully insured supplemental fertility plan for small employers, celebrating 10 years in business.
PGNYconference callQ1 2026 earnings
BenzingaBenzinga··Lekha Gupta

Hologic Goes Private in $18.3B Blackstone-TPG Takeover

Hologic completes $18.3B private equity acquisition by Blackstone and TPG, with shareholders receiving $76 per share plus conditional payments.
BXTPGHOLXacquisitiondelisting
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Bet on Organon Stock Signals Turnaround Faith Despite 61% Collapse

Sio Capital Management invested $24.53 million in Organon ($OGN) at $6.03/share, betting on turnaround potential despite 61% annual decline. Company maintains flat 2026 guidance with $1.9B adjusted EBITDA.
OGNvalue investinginstitutional investment
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider Research

Uterine Fibroid Treatment Market Poised for 7.63% Annual Growth Through 2033

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.
JNJPFEABBVSYKMDT+9market growthminimally invasive procedures